<SEC-DOCUMENT>0000899243-23-009251.txt : 20230321
<SEC-HEADER>0000899243-23-009251.hdr.sgml : 20230321
<ACCEPTANCE-DATETIME>20230321062144
ACCESSION NUMBER:		0000899243-23-009251
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20230316
FILED AS OF DATE:		20230321
DATE AS OF CHANGE:		20230321

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Folinsbee Thomas
		CENTRAL INDEX KEY:			0001706382

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40466
		FILM NUMBER:		23747792

	MAIL ADDRESS:	
		STREET 1:		2724 HARDY CRESCENT
		CITY:			NORTH VANCOUVER
		STATE:			A1
		ZIP:			V7H 1K2

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Summit Healthcare Acquisition Corp.
		CENTRAL INDEX KEY:			0001839185
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		UGLAND HOUSE, BOX 309
		CITY:			GRAND CAYMAN
		STATE:			E9
		ZIP:			KY1-1104
		BUSINESS PHONE:		212-446-4800

	MAIL ADDRESS:	
		STREET 1:		UGLAND HOUSE, BOX 309
		CITY:			GRAND CAYMAN
		STATE:			E9
		ZIP:			KY1-1104
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0407</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2023-03-16</periodOfReport>

    <notSubjectToSection16>1</notSubjectToSection16>

    <issuer>
        <issuerCik>0001839185</issuerCik>
        <issuerName>Summit Healthcare Acquisition Corp.</issuerName>
        <issuerTradingSymbol>SMIHU</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001706382</rptOwnerCik>
            <rptOwnerName>Folinsbee Thomas</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O SUMMIT HEALTHCARE ACQUISITION CORP.</rptOwnerStreet1>
            <rptOwnerStreet2>UNIT 1101, 11TH FLOOR, 1 LYNDHURST TOWER</rptOwnerStreet2>
            <rptOwnerCity>CENTRAL, HONG KONG</rptOwnerCity>
            <rptOwnerState>K3</rptOwnerState>
            <rptOwnerZipCode></rptOwnerZipCode>
            <rptOwnerStateDescription>HONG KONG</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Class B Ordinary Shares</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2023-03-16</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>D</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F2"/>
                <footnoteId id="F3"/>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>25000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F2"/>
                    <footnoteId id="F3"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F1"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Class A Ordinary Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>25000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>0</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">As described in the prospectus for the initial public offering (File No. 333-255722) of Summit Healthcare Acquisition Corp. (&quot;SMIH&quot;) under the heading &quot;Description of Securities--Founder Shares,&quot; the Class B ordinary shares, par value $0.0001 per share, automatically converted into Class A ordinary shares, par value $0.0001 per share, of SMIH at the time of the SMIH's initial business combination, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights.</footnote>
        <footnote id="F2">On March 16, 2023, pursuant to a Business Combination Agreement dated as of September 29, 2022 (the &quot;Business Combination Agreement&quot;), by and among SMIH, YishengBio Co., Ltd (&quot;YS Biopharma&quot;), Oceanview Bioscience Acquisition Co., Ltd., a direct wholly owned subsidiary of YS Biopharma (&quot;Merger Sub I&quot;) and Hudson Biomedical Group Co., Ltd., a direct wholly owned subsidiary of YS Biopharma (&quot;Merger Sub II&quot;), (i) Merger Sub I merged with and into SMIH (the &quot;First Merger&quot;), with SMIH surviving the First Merger as the surviving entity (the &quot;Surviving Entity&quot;) and remaining as a wholly-owned subsidiary of YS Biopharma and (ii) the Surviving Entity merged with and into Merger Sub II (the &quot;Second Merger&quot;), with Merger Sub II surviving the Second Merger as the surviving company (the &quot;Surviving Company&quot;) and remaining as a wholly-owned subsidiary of YS Biopharma.</footnote>
        <footnote id="F3">(Continued from Footnote 2) Immediately before the effective time of the First Merger, an aggregate of 1,446,525 Class B ordinary shares held by Summit Healthcare Acquisition Sponsor LLC, a Cayman Islands limited liability company (the &quot;Sponsor&quot;) was surrendered for nil consideration, and after such surrender, each Class B ordinary share ceased to be outstanding and automatically converted into the right to receive one ordinary share of YS Biopharma.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Bo Tan, as attorney-in-fact for Folinsbee Thomas</signatureName>
        <signatureDate>2023-03-21</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
